UBS Group AG Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

UBS Group AG boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report) by 37.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 469,316 shares of the biopharmaceutical company’s stock after purchasing an additional 128,595 shares during the quarter. UBS Group AG owned about 0.40% of Catalyst Pharmaceuticals worth $7,889,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CPRX. Parkside Financial Bank & Trust bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $31,000. Nisa Investment Advisors LLC boosted its position in Catalyst Pharmaceuticals by 306.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 3,829 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $123,000. Linden Thomas Advisory Services LLC bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $186,000. Finally, PNC Financial Services Group Inc. boosted its position in Catalyst Pharmaceuticals by 42.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 3,354 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $16.04 on Wednesday. The stock has a 50-day simple moving average of $15.66 and a two-hundred day simple moving average of $15.19. The firm has a market capitalization of $1.89 billion, a P/E ratio of 30.06, a PEG ratio of 1.37 and a beta of 0.73. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $11.41 and a fifty-two week high of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.31. The business had revenue of $98.51 million during the quarter, compared to analyst estimates of $97.24 million. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. As a group, analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.78 earnings per share for the current year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the transaction, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

CPRX has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. StockNews.com cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Monday. Finally, Bank of America assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $26.71.

Check Out Our Latest Stock Report on CPRX

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Featured Articles

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.